Addex Therapeutics LtdADXNNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank26
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P26
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -27.00% |
| Q2 2025 | 29.88% |
| Q1 2025 | -2441.63% |
| Q4 2024 | 94.09% |
| Q3 2024 | 85.54% |
| Q2 2024 | -25.71% |
| Q1 2024 | -252.01% |
| Q4 2023 | 72.34% |
| Q3 2023 | 18.34% |
| Q2 2023 | -16.88% |
| Q1 2023 | 23.19% |
| Q4 2022 | -14.17% |
| Q3 2022 | 53.85% |
| Q2 2022 | -20.35% |
| Q1 2022 | -64.51% |
| Q4 2021 | -15.99% |
| Q3 2021 | 60.65% |
| Q2 2021 | -133.03% |
| Q1 2021 | -492.83% |
| Q4 2020 | 127.56% |
| Q3 2020 | 58.52% |
| Q2 2020 | -48.23% |
| Q1 2020 | -18282.40% |
| Q4 2019 | 100.47% |
| Q3 2019 | -136.49% |
| Q2 2019 | 18.85% |
| Q1 2019 | -178.30% |
| Q4 2018 | -0.00% |
| Q3 2018 | -151.11% |
| Q2 2018 | 0.00% |
| Q1 2018 | 426.73% |
| Q4 2017 | 0.00% |
| Q3 2017 | -5.10% |
| Q2 2017 | 0.00% |
| Q1 2017 | 16.79% |
| Q4 2016 | 0.00% |
| Q3 2016 | 12.96% |
| Q2 2016 | 0.00% |
| Q1 2016 | -21.01% |
| Q4 2015 | 0.00% |